top of page
5 hours ago

From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi

CEO Jaewoo Kang, a computer scientist, describes AIGEN's computational heavy platform. Plus, he discusses three of the most advanced programs: a pan-KRAS inhibitor, USP1, and developing linkers and payloads to help Hanmi with ADCs.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh

bottom of page